Home › Research › Topics › bace1-inhibitors
bace1-inhibitors
5 studies tagged bace1-inhibitors, dated 2012-07-10 to 2016-11-01. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients 2016-11-01
- 1,4-Oxazine β-Secretase 1 (BACE1) Inhibitors: From Hit Generation to Orally Bioavailable Brain Penetrant Leads 2015-10-10
- BACE1 inhibitor drugs in clinical trials for Alzheimer's disease 2014-12-24
Studies
5 studies carry this tag.
Date range
2012 to 2016
Top journals
- Alzheimer's research & therapy 1
- Clinical pharmacology in drug development 1
- Journal of medicinal chemistry 1
- Molecules (Basel, Switzerland) 1
- Science translational medicine 1
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
β-Amyloid (Aβ) peptides are thought to be critically involved in the etiology of Alzheimer's disease (AD).
-
1,4-Oxazines are presented, which show good in vitro inhibition in enzymatic and cellular BACE1 assays.
-
β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is the β-secretase enzyme required for the production of the neurotoxic β-amyloid (Aβ) peptide that is widely considered to have a crucial early role in the etiology of Alzheimer's disease (AD).
-
Modulating deposition of Aβ-containing plaques in the brain may be beneficial in treating Alzheimer's disease. β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors have been shown to reduce Aβ in plasma and CSF in healthy volunteers.
-
Efforts to discover new drugs for Alzheimer's disease emphasizing multiple targets was conducted seeking to inhibit amyloid oligomer formation and to prevent radical formation.